Aurobindo Pharma's Q1 FY26 PBT dropped 8.8% YoY; Europe and ARV segments showed robust growth amid margin pressures.

• European revenue grew 18% YoY to Rs 2,338 crore; US sales declined 1.9%, impacted by seasonal and destocking effects.
• EBITDA margin shrank 102 bps YoY to 20.4%; API business revenue fell 16.1% while ARV business jumped 55.2%.
• Interim dividend of Rs 4/share announced; record date set as 8 August, payout by 21 August 2025.